GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Retained Earnings

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Retained Earnings : $1,758 Mil (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Santen Pharmaceutical Co's retained earnings for the quarter that ended in Dec. 2023 was $1,758 Mil.

Santen Pharmaceutical Co's quarterly retained earnings declined from Jun. 2023 ($1,717 Mil) to Sep. 2023 ($1,702 Mil) but then increased from Sep. 2023 ($1,702 Mil) to Dec. 2023 ($1,758 Mil).

Santen Pharmaceutical Co's annual retained earnings declined from Mar. 2021 ($2,514 Mil) to Mar. 2022 ($2,450 Mil) and declined from Mar. 2022 ($2,450 Mil) to Mar. 2023 ($1,781 Mil).


Santen Pharmaceutical Co Retained Earnings Historical Data

The historical data trend for Santen Pharmaceutical Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Retained Earnings Chart

Santen Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,327.24 2,539.51 2,513.71 2,449.68 1,781.11

Santen Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,849.98 1,781.11 1,716.64 1,702.50 1,758.33

Santen Pharmaceutical Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Santen Pharmaceutical Co  (OTCPK:SNPHY) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood 04-23-2020

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood 04-23-2020